Abnormal Levels of Pepsinogen I and Gastrin 17 in a case of Ménétrier Disease Pepsinogen I and G17 in Ménétrier Disease.

Main Article Content

Pellegrino Crafa https://orcid.org/0000-0001-8603-863X
Marilisa Franceschi
Lorella Franzoni
Francesco Di Mario


Ménétrier Disease, pepsinogen I, Gastrin 17


Background and aim: We describe a case of Ménétrier disease, occurred in female patient.

Methods:  We decide to assess by non-invasive way (serum pepsinogens and gastrin 17) the secretory status of gastric mucosa, to confirm previous data of the literature, claiming high levels of both acid secretion and hypergastrinemia in this rare pathological condition.

Results and Conclusion: We find in the subject the highest values of pepsinogen 1 – a marker of acid secretion – never described in the literature to our knowledge: 1940 mcg/L, being normal values ranging from 30-160 mcg/L. Similarly, gastrin 17, produced 90% in the antrum and responsible for negative acid feedback, was very high: 139 pg/L, ranging normal values between 1-10 pg/L. (www.actabiomedica.it)


Download data is not yet available.
Abstract 3 |


1 Gore M, Bansal K., Jadhav N. Menetrier Disease. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2021 Jan.2020 Sep 23. PMID: 33085301
2 Meuwissen S G , Ridwan B U, Hasper H J, Innemee G. Hypertrophic protein-losing gastropathy. A retrospective analysis of 40 cases in The Netherlands. The Dutch Ménétrier Study Group. Scand J Gastroenterol Suppl. 1992;194:1-7.
3 Almazar AE, Penfield JD, Saito YA, Talley NJ. Survival Times of Patients With Menetrier's Disease and Risk of Gastric Cancer. Clin Gastroenterol Hepatol. 2020 Mar 14;
4 Nomura S, Settle SH, Leys CM, et al. Evidence for repatterning of the gastric fundic epithelium associated with Menetrier’s disease and TGF-alpha overexpression. Gastroenterology 2005;128:1292–305.
5 M. Azer, A. Sultan, K. Zalata, I. Abd El-Haleem, A. Hassan, G. El-Ebeidy, A case of Menetrier’s disease without Helicobacter pylori or hypoalbuminemia, Int. J.Surg. Case Rep. 17 (2015) 58–60,
6 C. Parianos, C. Aggeli, A. Sourla, G.N. Zografos, Total gastrectomy for the treatment of Menetrier’s disease persistent to medical therapy: a case report. Int. J. Surg. Case Rep. 73 (2020) 95–99.
7 Dempsey P. J., Goldenring J. R., Soroka C. J., Modlin I. M., McClure R. W., Lind C.
D., Ahlquist D. A., Pittelkow M. R., Lee D. C., Sandgren E. P., Page D. L., and Coffey
R. J. Possible role of transforming growth factor a in the pathogenesis of Menetrier’s
disease: supportive evidence from humans and transgenic mice. Gastroenterology,
703: 1950-1963, 1992.
8 Di Mario F, Ingegnoli A, Altavilla N, Cavallaro LG, bertolini S, Merli R, Cavestro GM, Iori V, Maino M, Leandro G, Franzè A Influence of antisecretory treatment with proton pump inhibitors on serum pepsinogen I levels Fundam Clin Pharmacol. 2005 Aug;19(4):497-501
9 Preston SR, Woodhouse LF, Jones-Blackett S, Wyatt JI, and. Primrose JN High Affinity Binding Sites for Gastrin Releasing Peptide on Human Gastric Cancer and Mènètrier’s Mucosa1 Canc. Res. 1993. 53. 5090-5092

Most read articles by the same author(s)

1 2 3 4 5 > >>